A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

India has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja ...

For patients with relapsed/refractory large B-cell lymphoma, access to lifesaving CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be limited by post-infusion monitoring protocols ...

Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round, which will enable the company ...

Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

Linda Nolan has spent two years sharing every twist and turn of her cancer journey in her Daily Mirror column, Straight From ...